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Disclosures
• Disclosure of Relevant Financial Relationships: The presenter has
no financial relationships to disclose.
• Disclosure of Off‐Label and /or Investigative Uses: The presenter
will not discuss off label use and /or investigational use in this
presentation.
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Objectives
•
•
•
•

Analyze case studies involving genomic medicine.
Appraise the validity of the genomic information in each case.
Discuss the relevant bioethical issues in each case.
Draft an educational format for genomics in primary care
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ACCE Framework
 Analytical validity – genomic test results need to be
accurate and reliable.
 Clinical validity – reliable results are of consistent clinical
significance.
 Clinical utility – there is a clear benefit for intervention
based on genomic test results.
 Ethical, legal, and social implications are openly discussed.
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Tiered Approach to Integrating
Genomics into Practice
• Tier 1 – recommended for clinical use by evidence‐based
panels and supported by systematic review of evidence
• Tier 2 – validity and promising evidence of clinical utility, but
lack evidence‐based recommendations
• Tier 3 – inadequate validity or utility
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Caveat
•Genomic makeup in complex
disease is probabilistic, not
deterministic.
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Case No. 1
 Andrea is a 34‐year‐old bank executive.
 Her mother was diagnosed with breast cancer six years ago
and is now disease free.
 Her father has Type II Diabetes.
 Her maternal grandfather is in a nursing home dementia
unit.
 She jogs for exercise 5 days a week. She has about 5 drinks a
week, usually wine. She occasionally smokes when drinking.
 Her BMI is 23 and she has no know medical problems.
 Adapted from Nuffield Council on Bioethics
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Case No. 1
• Recently, she received an email offering her personal genetic
testing to screen for genes that may put her at risk for future
disease. The price was affordable and the process seemed
simple. Curious to know her risk, she requests a kit and sends
in a saliva sample.
• She makes an appointment to discuss her results with you.
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Andrea’s Results
Est. Lifetime Risk

Avg. Population Risk

Alzheimer’s Disease

Condition

19%

11%

Breast Cancer

13%

13%

16.5%

19%

Type II Diabetes
Heart Attack

38%

28%

Hypertension

40%

40%

Lung Cancer

4%

7.5%

Osteoarthritis

34%

33%
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Questions To Consider
• Does this testing benefit Andrea?
• She is concerned she is at increased risk for Alzheimer’s
Disease and Heart Attack. How would you discuss her
increased risks?
• Are there modifiable environmental risks that might interact
with genetic risks?
• Her husband’s family has a history of premature MI (i.e. men
younger than 55), and he takes cholesterol medication. She
wants to know if she should have genetic testing for her 6‐
year‐old son. What is your advice?
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Case No. 2
• James is a 42‐year‐old man coming in for his insurance‐
approved wellness exam.
• He has a history of hypertension. He smokes a pack of
cigarettes a day, does not exercise and has 1‐2 drinks a day. He
describes himself as a “meat and potatoes” man and only
occasionally eats fruits and vegetables.
• He has had no previous cancer screenings.
• His BMI is 28.
• Adapted from the National Coalition for Health Professional Education in Genetics
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Case No. 2
• In his family history, James’ older brother was diagnosed with
colorectal cancer two years ago, at the age of 45. His mother
was diagnosed with endometrial cancer at age 49. A paternal
aunt was diagnosed with breast cancer at age 63. His maternal
grandmother was diagnosed with pancreatic cancer at age 67.
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Questions to Consider
• Is James at average, increased (moderate) or high risk for
colorectal cancer (CRC)?
• How should James be screened for CRC?
• Would you recommended for genetic counseling/testing for
James?
• What would you recommend for James’ 46‐year‐old sister?
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Creating a Pedigree
Female

Identified Patient
Male

Unknown
gender

Deceased
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5

Pancreatic
Cancer
Age 67

Endometrial
Cancer
Age 49

Breast Cancer
Age 63

Colorectal
Cancer
Age 45
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Pancreatic
Cancer
Age 67

Endometrial
Cancer
Age 49

Breast Cancer
Age 63

Colorectal
Cancer
Age 45
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Pancreatic
Cancer
Age 67

Endometrial
Cancer
Age 49

Breast Cancer
Age 63

Colorectal
Cancer
Age 45
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Case No. 3
• Jasmine is a 22‐year‐old woman went to Planned Parenthood
to start oral contraceptives.
• On her intake sheet at Planned Parenthood, she checked the
box for a family history of blood clotting.
• She was told she had to have her doctor’s permission before
starting because of that history.
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Case No. 3
• Jasmine is a smoker, about 10 cigarettes a day.
• Her older sister has a six‐month‐old boy. The pregnancy was
complicated by preecclampysia
• On her mother’s side of the family, her uncle had a blood clot
in his 30s and another in his 40s, and is now on blood thinners
• Her grandmother had a stroke at age 59.
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Questions to Consider
• If Jasmine stops smoking, has she eliminated her risk for
developing venous thromboembolism on OCPs?
• Should anyone in Jasmine’s family be tested for inherited
thrombophilias?
• Should Jasmine be on anticoagulants?
• What forms of birth control would you recommend for
Jasmine?

21

7

Developing Genomic Education
and Integration for Primary
Care
• What key elements need to go into primary care
education to manage genomics?
• Consider attitudes, knowledge, and skills.
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Attitudes
• All health professionals should:
• appreciate the sensitivity of genetic information and the need for
privacy and confidentiality.
• seek coordination and collaboration with an interdisciplinary
team of health professionals.
• Core Competencies for All Health Care Professionals. National
Coalition for Health Professional Education in Genetics. 2007.
www.nchpeg.org
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Knowledge
• How identification of disease‐associated genetic
variations facilitates development of prevention,
diagnosis, and treatment options.
• The interaction of genetic, environmental, and
behavioral factors in predisposition to disease,
onset of disease, response to treatment, and
maintenance of health.
• The difference between clinical diagnosis of
disease and identification of genetic
predisposition to disease (genetic variation is not
strictly correlated with disease manifestation).
• Core Competencies for All Health Care Professionals.
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Knowledge
• The potential physical and/or psychosocial
benefits, limitations, and risks of genetic
information for individuals, family members, and
communities.
• The ethical, legal and social issues related to
genetic testing and recording of genetic
information (e.g., privacy, the potential for
genetic discrimination in health insurance and
employment).
• Core Competencies for All Health Care Professionals.
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Skills
• Explain effectively the reasons for and benefits of genetic
services.
• Assure that the informed‐consent process for genetic testing
includes appropriate information about the potential risks,
benefits, and limitations of the test in question.
• Core Competencies for All Health Care Professionals.
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Lynch syndrome

Lynch syndrome/hereditary nonpolyposis colon cancer fact sheet
Clinical features
Lynch syndrome (LS) is caused by a mutation in a mismatch repair (MMR) gene. Individuals with
LS are at increased risk for colon and other cancers, including gastric, urinary tract, brain, small
bowel, pancreatic, hepatobiliary and sebaceous carcinoma. Women with LS are at increased risk for
endometrial and ovarian cancer.
Diagnosis of LS
An individual should meet Amsterdam II criteria or have a mutation that is identified by molecular
genetic testing of the MMR genes.
Clinical diagnosis of LS: The Amsterdam II criteria define the minimum requirements for a clinical
diagnosis of Lynch syndrome.
There should be at least three relatives with a Lynch/HNPCC-associated cancer (cancer of the colorectum,
endometrium, small bowel, ureter or renal pelvis) and …
• One should be a first-degree relative to the other two
• At least two successive generations should be affected
• At least one should be diagnosed before age 50
• Familial adenomatous polyposis should be excluded
• Tumors should be verified by pathological examination

Inheritance
Autosomal dominant
Gene(s)
Mismatch repair genes
MLH1 & MSH2 (mutation present in about 90 percent of LS families)
MSH6 (mutation present in about 7–10 percent of LS families)
PMS2 (mutation present in <5 percent of LS families)
Non-mismatch repair genes
EPCAM (mutation present in 1–3 percent of LS families)
Genetic testing
Direct gene testing is available commercially. To identify colorectal cancer patients who may
have LS, the current recommendations are to begin by ordering microsatellite instability (MSI) or
immunohistochemistry (IHC) testing on the tumor sample. This can be performed by a pathologist
on archived tumor blocks from a surgical specimen. These tests detect either an increased number of
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microsatellite repeats (MSI, a hallmark of impaired mismatch repair gene activity), or the absence of
the protein products of the mismatch repair genes (IHC). MSI/IHC have known utility for colorectal
and endometrial cancers but are not routinely recommended for other cancers. If either test is
positive, meaning that the mismatch repair genes appear to be impaired, then continue on to genetic
testing that can determine which mismatch repair gene is mutated. Whenever possible, begin this
genetic testing on an affected family member. The identification of a mutation confirms the diagnosis
of LS. If a mutation is not identified, a diagnosis of LS can neither be confirmed nor ruled out; this
result must be interpreted in the context of the patient’s MSI/IHC results, family and personal history
and test limitations. See “Overview of testing for Lynch syndrome tool” for more information.
Colon cancer risk
General population

Lynch syndrome

Mean age at cancer
onset (LS)

Male

5.6%

28–75%*

44–61 years

Female

5.3%

24–52%*

44–61 years

*lower risks w/MSH6, PMS2 gene mutations

Associated cancer risks*
Type of cancer

General population

Lynch syndrome

Mean age at cancer
onset (LS)

Endometrium

2.7%

27–71%

46–62 years

Ovary

1.6%

3–13%

43 years

Other (stomach,
hepatobilliary,
urinary tract, etc.)

<1%

Stomach: 2–19%
Urinary tract: 1–12%
Others: 1–7%

Variable

*Increased risks for additional primary colon cancers

Non-cancer findings: keratoacanthomas, sebaceous adenomas
Screening recommendations (See “Screening guidelines tool”):
1. Colonoscopy: every one to two years starting at age 20–25 or two to five years prior to the
earliest colon cancer in the family if diagnosed under age 25.
2. If colon cancer is found, consider removal of entire colon and continue annual screening for
rectal cancer.
3. Consider prophylactic removal of the colon in cases where regular screening with colonoscopy
cannot be performed.
4. Females: consider annual endometrial sampling and transvaginal ultrasound.
5. Consider prophylactic hysterectomy with bilateral salpingo-oophorectomy after childbearing
is complete.
6. Consider annual urinalysis.
7. Consider EGD with extended duodenoscopy and polypectomy at two to three year intervals
beginning at age 30.
Screening references:
NCCN Colorectal Cancer Screening Guidelines, V.2.2011.
nccn.org/professionals/physician_gls/f_guidelines.asp
ACG Guidelines for Colorectal Cancer Screening 2009.
http://s3.gi.org/physicians/guidelines/CCSJournalPublicationFebruary2009.pdf
Vasen, H., Watson, P., Mecklin, J.-P., & Lynch, H. (1999). New clinical criteria for hereditary nonpolyposis colorectal cancer
(HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology, 116(6), 1453–1456.
11-0456:2/12:jt:Updated Feb 2012
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Inherited Thrombophilia Fact Sheet
Inherited thrombophilia is a genetic tendency toward venous thromboembolism (VTE) the usually
presents in patients under age 50 and is often recurrent.
The most frequent causes are mutations of Factor V Leiden or prothrombin genes, which account for 50
to 60 percent of cases. Other defects in protein S, protein C, and antithrombin (i.e. antithrombin III)
account for most of the rest.
About 50% of the VTE events in patients with inherited thrombophilia have an acquired risk factor, such
as smoking, oral contraceptive use, recent surgery, or pregnancy.
Genetic causes of thrombophilia
Mechanism/factor
Population Prevalence
Deficiency of anticoagulants
Antithrombin III
< 1%
Protein C
< 1%
Protein S
1%
Mechanism/factor
Population Prevalence
Increased procoagulants
Factor V Leiden
3-7%
Prothrombin G20210A
1-4%
Elevated homocysteine
10-15%

Inheritance Pattern

Risk of VTE by Age 60

Autosomal dominant
Autosomal dominant
Autosomal dominant
Inheritance Pattern

60%
50%
33%
Lifetime Risk of VTE

Autosomal dominant
Autosomal dominant
Multifactorial

5-20%
10-20%
Not yet determined
Adapted from Up To Date

Genetic Diagnostic Testing and Presymptomatic Testing
Genetic diagnostic testing is done when a patient is offered a genetic test based on symptoms and signs
already present. The purpose is to rule out a genetic cause of current symptoms.
Presymptomatic testing is when an at-risk individual, who is asymptomatic at the time, carries a mutant
gene that may increase the risk of developing disease at some point in the future. Typically, an effected
family member has had a positive genetic diagnostic test.

“Red Flags” Suggesting Inherited Thrombophilia
Recurrent VTE, or spontaneous VTE
VTE at a young age
Recurrent miscarriage
Thrombosis in unusual sites (e.g. sagittal sinus) or multiple thrombi
Coronary or cerebral thrombosis at an early age (Men < 50, Women < 60)

Adapted from Genetics in the Physician Assistance’s Practice

